12.51
-0.29 (-2.27%)
-0.29 (-2.27%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 601,522 |
|
|||||
| News | - | ||||||
| Day High | 13.52 | Low High |
|||||
| Day Low | 12.49 | ||||||
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aclaris Therapeutics Inc | ACRS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| -0.29 | -2.27% | 12.51 | 17:26:45 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 13.06 | 12.49 | 13.52 | 12.51 | 12.80 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,125 | 601,522 | $ 13.01 | $ 7,825,701 | - | 3.27 - 30.375 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:12:56 | priorref | 3,072 | $ 12.51 | USD |
Period:
Draw Mode:
Aclaris Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 765.95M | 61.23M | 52.14M | $ 6.48M | $ - | -1.20 | -7.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -1.04k | 4.10% |
Aclaris Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACRS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 12.75 | 13.52 | 12.01 | 12.78 | 388,926 | -0.24 | -1.88% |
| 1 Month | 16.33 | 17.22 | 12.01 | 14.47 | 418,284 | -3.82 | -23.39% |
| 3 Months | 17.07 | 19.97 | 12.01 | 16.49 | 442,581 | -4.56 | -26.71% |
| 6 Months | 22.29 | 24.00 | 12.01 | 17.04 | 566,129 | -9.78 | -43.88% |
| 1 Year | 3.37 | 30.375 | 3.27 | 18.01 | 1,191,547 | 9.14 | 271.22% |
| 3 Years | 9.41 | 30.375 | 0.70 | 9.47 | 895,742 | 3.10 | 32.94% |
| 5 Years | 29.78 | 33.25 | 0.70 | 11.64 | 655,943 | -17.27 | -57.99% |
Aclaris Therapeutics Description
| Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are ATI-450, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. |
